MicroRNA-29c-3p inhibits osteosarcoma cell proliferation through targeting PIK3R3

被引:3
作者
Ma, H-Z [1 ]
Wang, J. [1 ]
Shi, J. [1 ]
Zhang, W. [1 ]
Zhou, D-S [1 ]
机构
[1] Shandong First Med Univ, Dept Orthoped Surg, Shandong Prov Hosp, Jinan, Peoples R China
关键词
MicroRNA-29c-3p; PIK3R3; OS; Malignant progression; INVASION; MIGRATION;
D O I
10.26355/eurrev_202003_20489
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: MicroRNAs (mlR- NAs) are endogenous, non-coding small RNAs involving in pathological regulation. Previous studies have shown that microRNA-29c-3p is a tumor-suppressor gene. However, the role of microRNA-29c-3p in osteosarcoma (OS) has not been reported. This study aims to investigate the potential influence of microRNA-29c-3p on the progression of OS. PATIENTS AND METHODS: Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) was applied to examine microRNA-29c-3p levels in 40 matched pairs of OS tumor tissues and adjacent ones. The correlation between microRNA-29c-3p expression and clinical indicators in OS patient was analyzed. At the same time, qRTPCR was used to detect microRNA-29c-3p level in OS cell lines. In addition, microRNA-29c-3p knockdown and the overexpression models were constructed in OS cell lines. The effects of microRNA-29c-3p on the biological functions of OS cells were analyzed via cell counting kit-8 (CCK-8) and transwell assays. Finally, the potential mechanism underlying microRNA-29c-3p in OS was explored by Western Blot and cell recovery experiment. RESULTS: QRT-PCR results revealed that microRNA-29c-3p level in OS tumor tissues was conspicuously lower than that in adjacent tissues. Compared with OS patients with the high expression of microRNA-29c-3p, those with low expression of microRNA-29c-3p had a higher incidence of distant metastasis and worse overall survival. Cell proliferative capacity and invasiveness in OS were enhanced after knockdown of microRNA-29c-3p; while the opposite results were observed after the overexpression of microRNA-29c-3p. QRT-PCR results revealed that microRNA-29c-3p negatively regulated PIK3R3 expression in OS cells. Moreover, microRNA-29c-3p and PIK3R3 levels were confirmed to be negatively correlated in OS tissues. In addition, cell reverse experiment demonstrated that PIK3R3 was responsible for the malignant progression of OS regulated by microRNA-29c-3p. CONCLUSIONS: MicroRNA-29c-3p expression was reduced in OS, and conspicuously associated with distant metastasis and poor prognosis. MicroRNA-29c-3p might inhibit the malignant progression of OS by modulating PIK3R3 expression.
引用
收藏
页码:2239 / 2247
页数:9
相关论文
共 21 条
[1]  
[Anonymous], 2017, ONCOTARGET
[2]   MicroRNAs as Therapeutic Agents: The Future of the Battle Against Cancer [J].
Biswas, Sumit .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2018, 18 (30) :2544-2554
[3]   Role of autophagy in osteosarcoma [J].
Camuzard, Olivier ;
Santucci-Darmanin, Sabine ;
Carle, Georges F. ;
Pierrefite-Carle, Valerie .
JOURNAL OF BONE ONCOLOGY, 2019, 16
[4]  
Chao LM, 2018, EUR REV MED PHARMACO, V22, P7205, DOI 10.26355/eurrev_201811_16254
[5]   p53 target miR-29c-3p suppresses colon cancer cell invasion and migration through inhibition of PHLDB2 [J].
Chen, Geng ;
Zhou, Tong ;
Li, Yang ;
Yu, Zhenxiang ;
Sun, Liankun .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 487 (01) :90-95
[6]   Drug resistance-related microRNAs in osteosarcoma: Translating basic evidence into therapeutic strategies [J].
Chen, Ruiling ;
Wang, Gangyang ;
Zheng, Ying ;
Hua, Yingqi ;
Cai, Zhengdong .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2019, 23 (04) :2280-2292
[7]  
Chen YG, 2018, J BUON, V23, P735
[8]   Osteopontin as a biomarker for osteosarcoma therapy and prognosis [J].
Han, Xingwen ;
Wang, Wenji ;
He, Jingjing ;
Jiang, Lei ;
Li, Xun .
ONCOLOGY LETTERS, 2019, 17 (03) :2592-2598
[9]  
IRAc SE, 2019, VET SCI, V6
[10]   Angiogenesis Process in Osteosarcoma: An Updated Perspective of Pathophysiology and Therapeutics [J].
Li, Yu-sheng ;
Liu, Qing ;
Tian, Jian ;
He, Hong-bo ;
Luo, Wei .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2019, 357 (04) :280-288